Comparison of the Effects of Potential Parenteral Vehicles for Poorly Water Soluble Anticancer Drugs (Organic Cosolvents and Cyclodextrin Solutions) on Cultured Endothelial Cells (HUV-EC)
- 1 September 1998
- journal article
- research article
- Published by American Geophysical Union (AGU) in Journal of Pharmaceutical Sciences
- Vol. 87 (9) , 1138-1143
- https://doi.org/10.1021/js9704442
Abstract
The effect of dilution of parenteral vehicles (organic cosolvent and 0.1 M cyclodextrin solutions) on cultured endothelial cells (HUV-EC) were compared in vitro. Cell morphology was observed by phase contrast light microscopy and cell viability by measuring 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) reduction or intracellular lactate dehydrogenase (LDH) activity and total protein. Disruption of the HUV-EC monolayer was observed at dilutions of 1 in 20 for the melphalan and PEP cosolvents, 1 in 100 for an investigational drug cosolvent, and 1 in 10 for 0.1 M dimethyl-beta-cyclodextrin. In comparison, 0.1 M SBE7M- and HP-beta-cyclodextrin caused only minor disruption at a 1 in 5 dilution. MTT reduction, intracellular LDH, and total protein were decreased following exposure to 1 in 10 dilution of the melphalan cosolvent. For other test solutions, intracellular LDH activity and total protein were measured, and reductions were observed following exposure to 1 in 10, 20, and 50 dilutions of the investigational drug cosolvent and 1 in 5 dilution of DM-beta-cyclodextrin (0.1 M). At a dilution of 1 in 10, no delayed toxicity was observed for cosolvents or cyclodextrin solutions. Hence, 0.1 M SBE7M- or HP-beta-cyclodextrin formulations may be less damaging to the venous endothelium at the site of injection than organic cosolvent formulations.Keywords
This publication has 14 references indexed in Scilit:
- Molecular Structure of the Apical Junction Complex and Its Contribution to the Paracellular BarrierJournal of Pharmaceutical Sciences, 1997
- Pharmaceutical Applications of Cyclodextrins. 2. In Vivo Drug DeliveryJournal of Pharmaceutical Sciences, 1996
- Predicting Injection Site Muscle Damage III: Evaluation of Intramuscular Formulations in the L6 Cell ModelPharmaceutical Research, 1996
- Preliminary Safety Evaluation of Parenterally Administered Sulfoalkyl Ether β-Cyclodextrin DerivativesJournal of Pharmaceutical Sciences, 1995
- Differential Effects of Sulfate and Sulfobutyl Ether of β-Cyclodextrin on Erythrocyte Membranes in VitroPharmaceutical Research, 1995
- Evaluation of the cytotoxicity of cyclodextrins and hydroxypropylated derivativesInternational Journal of Pharmaceutics, 1994
- Evaluation of surfactant cytotoxicity potential by primary cultures of ocular tissues: I. Characterization of rabbit corneal epithelial cells and initial injury and delayed toxicity studiesToxicology, 1992
- An In Vitro Model to Evaluate Muscle Damage Following Intramuscular InjectionsPharmaceutical Research, 1989
- Pharmaceutical evaluation of hydroxyalkyl ethers of β-cyclodextrinsInternational Journal of Pharmaceutics, 1988
- Cancer chemotherapy agent-induced perivenous extravasation injuriesPublished by Oxford University Press (OUP) ,1987